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Introduction
Cystic fibrosis is one of the most common genetic meta-
bolic disorders, following the pattern of autosomal reces-
sive inheritance and leading to premature death. The
incidence of cystic fibrosis in Poland is 1:2500 live births
[1]. A mutation in the CFTR (Cystic Fibrosis Trans-
membrane Conductance Regulator) gene, acting as a cel-
lular chloride channel pore and ion transport regulator, is
the cause of the disease [2]. Over 1000 different muta-
tions in the CFTR gene have been described, of which
F508del accounts for almost 70% of all cases [3]. 
Malnutrition, delayed growth and delayed puberty
are commonly observed in children suffering from
cystic fibrosis [4-7]. However, the results of some
studies demonstrate that intensive medical care,
administered in specialized cystic fibrosis centers, sig-
nificantly improves growth rate and nutritional status,
sometimes to levels comparable to those observed in
the healthy population [8,9]. Considerable delays in
onset as well as disturbances of puberty are however
still noted in children with CF [10,11].
Longitudinal observation of growth and maturation
processes in children with CF reveals a delayed and
strongly reduced pubertal growth spurt [10,12-14].
Most marked growth delays were observed in patients
with F508del/F508del mutation types [12]. It should
be stressed that, in CF patients, decreased levels of
hormones crucial to the growth process have been
detected – i.e. insulin-like growth factors IGF-I, corre-
sponding binding proteins IGFBP3 and thyroid hor-
mones [15-18]. Slower development of II- and III-sex
characteristics has also been observed in children with
CF [19]. 
Menarcheal age in sick children is generally
delayed by 2 years in comparison with the healthy
child population and usually occurs after the age of 14
[4,19,20]. Malnutrition is the main cause for delayed
puberty in CF, but late menarche was also observed in
girls who manifested normal nutritional status in spite
of the disease [5,10]. The age at onset of menarche
depends on the type of mutation, and is most delayed
in patients with the F508del/ F508del genotype [10]. 
Puberty observations in CF adolescents have how-
ever proven equivocal with respect to clinical symp-
toms and disease severity. While some studies have
demonstrated a significant relationship between the
age of menarche and respiratory system condition –
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girls with worse respiratory parameters (low FEV1 val-
ues) were found to reach puberty later – other research
has shown no relationship between menarche and
severity of the disease [7,10]. 
Most studies concerning menarcheal age in female
children with CF were conducted on small study pop-
ulations and the occurrence of the first period was
determined exclusively by means of retrospective
analysis. The aim of this study was to assess the age
of menarche in 47 girls with cystic fibrosis using sta-
tus quo analysis, more appropriate and accurate in the
case of a developmental population. The relation-
ships between types of CFTR mutations and age at
the first menstruation as well as somatic parameter
values and respiratory system condition, were also
evaluated. 
Materials and methods
Material was based on somatic data gathered from the medical his-
tory records of 47 girls with cystic fibrosis, aged 11-18 years (mean
age 13.8±2.2 y.o.). All girls were patients of the Institute of
Mother and Child in Warsaw (Poland). In all patients, the diagno-
sis was confirmed by positive sweat tests. The mean age at the
moment of diagnosis was 4.5 years (minimum 1 month, maximum
15 years). All study subjects were Caucasian. Data for the study
were gathered in 2007 during standard developmental profile
assessment procedures. All girls as well as their parents/guardians
gave informed consent to the trial. 
Anthropometric measurements of height and body mass were
performed. Height measurements were taken using a stadiometer
with a 1mm accuracy, while body mass was assessed with a 0.1 kg
accuracy. All measurements were performed in accordance with
the methods described by Martin and Knusmann [21]. Body Mass
Index was accordingly calculated [BMI=body mass (kg)/body
height (m2)]. Anthropometric parameters were expressed in terms
of standard deviations away from age-specific and sex-specific ref-
erence means for the population of Poland [22].
Respiratory system deficiency was evaluated basing on
spirometry results. Recorded data included Forced Vital Capacity
(FVC) and Forced Expiratory Volume in one second (FEV1). All
spirometric parameters were measured using a Lungtest 1000
spirometer in accordance with the procedures recommended by the
Polish Respiratory Society [23]. All results were recorded as per-
centages of the predicted values, standardized for age, height and
gender [24].
Molecular DNA was analyzed in all patients in order to deter-
mine the type of CFTR gene mutation. The studies were carried out
at the Medical Genetics Laboratory of the Institute of Mother and
Child at the time the patients were admitted.
All patients were treated in accordance with current CF treat-
ment standards [25]. The therapeutic approach to the alimentary
tract included diet modification together with vitamin and enzyme
supplementation. Other therapy included: physiotherapy, nebulised
treatment and antibiotics in the case of bronchopulmonary compli-
cations, also in case of Pseudomonas aeruginosa chronic colo-
nization.
The age of menarche was determined using the status quo
(probit) method, asking girls about presence or lack of menstrua-
tion. Thus, each class included girls who menstruate as well as
those still pre-menarche. The age of menarche was also deter-
mined for the girls in the study group using probit analysis in
accordance with the method described by Finney [26]. Using the
probit method, the following menarcheal age distribution param-
eters were calculated: means probit-based value and standard
deviation. 
Statistical analysis. A comparison of the mean somatic and respi-
ratory parameter values was carried out using the Student's t-test.
Normality was analyzed using the Shapiro-Wilk test. The correla-
tion between CFTR mutation type and the onset of the first men-
struation was assessed with a χ2 test. In order to determine the way
menarche onset and type of CFTR mutation affect somatic and
spirometric parameters, a two-way analysis of variance was per-
formed. The R2 coefficient of determination indicated the percent-
age of variance of independent variables. Statistical significance
was considered when p<0.05. The analyses were carried out using
STATISTICA 8.0.
Results
From among the 47 girls aged 11 through 18, 20 study
subjects menstruated (42.5%). The mean age of
menarche calculated using probit analysis amounted to
14.65±1.21 years (Table 1).
Mean values of somatic and respiratory parameters
were compared in terms of menarche occurrence. 
Menstruating girls were found to be statistically
older and taller than their non-menstruating consorts.
Regarding body mass and BMI, a marked tendency
towards higher parameter values was noted in the men-
struating group, although the differences were not sta-
tistically significant. 
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Table 1. Number of menstruating study subjects with cystic fibro-
sis in subsequent age categories.
Statistically higher FVC% and FEV1% respiratory
parameters were found in menstruating study subjects
(Table 2).
In all girls, molecular DNA tests were performed in
order to determine the type of CFTR mutation. Three
study groups were formed depending on the DNA test
results. The first group (N=16; 34%) included study
subjects with the F508del/F508del genotype, a severe
mutation; the second group (N=16, 34%) those with
the F508del/Mt genotype, a less severe mutation
(where Mt signifies a mutation other than F508del, i.e.
R334W). The third group (n=15; 32%) included study
subjects with a Mt/Mt mutation type, i.e.
3849+10kbC → T/3849+10kbC → T, 
3849+10kbC → T/3659delC.
A significant correlation between the onset of
menarche and the type of CFTR mutation was found
(χ2=6.41, df=2, p=0.04) (Table 3). More non-menstru-
ating girls were observed in the F508del/F508del
mutation group. 
Table 4 presents the cumulative, independent influ-
ence of menarcheal onset and type of CFTR mutation
over somatic and spirometric parameters in study sub-
jects. The occurrence of the first period statistically
differentiated body height values, while no such influ-
ence was observed in terms of body mass, BMI or res-
piratory parameters. 
The type of CFTR gene mutation also statistically
differentiated respiratory parameter values: Forced
Vital Capacity (FVC%) and Forced Expiratory Volume
in one second (FEV1%) in the studied girls. The low-
est 
FVC% and FEV1% values were determined in
F508del/F508 patients, while the highest were in
F508del/Mt subjects (Fig. 1, 2).
A statistically significant correlation was observed
between onset of menarche and type of CFTR muta-
tion in terms of body height and weight. (Table 4).
Greatest height and weight deficiencies were observed
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Table 2. Mean height, body mass, BMI and respiratory parameter values, expressed in terms of standard deviations away from the means
of reference values for the population of Poland, in menstruating and non-menstruating girl with cystic fibrosis. 
*p<0.05, **p<0.01, ***p<0.001
Table 3. Number of menstruating and non-menstruating girls with
CF depending on CFTR mutation type.
Table 4. Results of two-way variance analysis of standardized anthropometric and respiratory parameters grouped according to menar-
che occurrence and type of CFTR mutation.
in non-menstruating F508del homozygotes (data not
shown). 
Discussion
Mean menarcheal age currently noted in the Polish
population varies from 12.7 y.o. in girls from Warsaw
to 13.4 y.o. in girls from the rural areas of the country
[27,28]. 
Thus, in comparison with the healthy child popula-
tion, girls with cystic fibrosis treated at the Institute of
Mother and Child experienced menarche with 2 years'
delay. In this group, the age of menarche, at
14.65±1.27 years old, confirms reports of delayed
puberty in patients with cystic fibrosis by other
authors, in spite of intensive medical care [19,29-31].
One of the works did note menarche onset in sick girls
within the healthy population age range, the authors
however failed to establish the mean menarcheal age
in study subjects [32]. 
Delayed puberty in CF patients has a complex eti-
ology. Malnutrition and related adipose tissue deple-
tion is the main factor answering for delayed onset and
disturbances in puberty [5]. Neinstein and al. [20] fur-
thermore demonstrated by means of step regression
analysis that body mass is the main predictor for
menarcheal age in girls with CF. According to the
Frisch-Revelle hypothesis, a critical body mass of 47.8
kg is indispensable for the onset of menstruation [33].
In those studies, as well as in the current analysis, body
mass in menstruating CF girls showed a marked ten-
dency towards reaching higher values as compared to
non-menstruating study subjects.
On the other hand, study subjects with very low
body mass were also present in the menstruating
group, while some non-menstruating girls had a body
mass exceeding the critical values, a fact which proves
that reaching the determined body mass is not the sole
criterion for menarche onset. It should be stressed that
a wide range of variance and high standard deviations
of the analyzed somatic parameters were noted in both
groups of girls, which indicates a relatively high level
of phenotypic differentiation in study subjects. It is
however common knowledge that body mass in CF
children has a tendency to oscillate depending on
abdominal and respiratory symptom intensification
[3]. 
In studies by Johannesson et al. [10], menarche in
girls with CF was delayed by almost 2 years in com-
parison with the healthy girl population (14.9 and 13.0
years respectively), although the groups did not differ
in terms of nutritional status. There are suspicions that
the mutated CFTR gene may cause disturbances in the
secretion of gonadotropin-releasing hormone (GnRH)
and thus delay puberty in spite of proper nutritional
status [10,34,35]. CFTR gene expression has been
observed in uterine endometrium and oviducts, but
remains unconfirmed in ovaries [36]. 
The Swedish study mentioned also reported the
longest delays in menarche in girls with the
F508del/F508del mutation type [10]. The researchers
sought interpretation of the results in differences in
resting energy expenditure in dependence of CFTR
mutation type. In CF patients, resting energy expendi-
ture is generally over 10% higher than in healthy sub-
jects due to breathing effort, which further disturbs
energy balance and hinders normal physical develop-
ment in children [8,37,38]. The greatest energy expen-
diture was determined in F508del homozygotes, which
may have contributed to even more severe delays and
disturbances in puberty in this patient group as com-
pared with other CFTR mutations [37]. 
In girls with cystic fibrosis, hormonal imbalances
tend to occur significantly more often than in the
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Fig. 1. FVC% values for different types of CFTR gene mutation
(means, standard deviations and 95% confidence intervals).
Fig. 1. FEV1% values for different types of CFTR gene mutation
(means, standard deviations and 95% confidence intervals).
healthy population, resulting in irregular menstrual
cycles and leading to the development of Polycystic
Ovary Syndrome (PCOS) [20,32,39]. In the hormonal
profile of 18 menstruating girls with cystic fibrosis
aged from 12 through 23, increased levels of LH,
FSH/LH and prolactin (PRL), as well as decreased
level of SHBG (sex hormone-binding globulin) were
observed [32]. In the same study, polycystic ovary syn-
drome was diagnosed in almost half of the patients,
without however typical symptoms in the form of hir-
sutism and acne on the account of low adipose tissue
quantity. 
Advances in pharmacological treatment and nutri-
tional approach (including amongst other things high
calorie diet implementation and chronic pancreatic
enzyme supplementation) considerably contribute to
the improvement of nutritional status in CF, sometimes
leading to the development of overweight or obese
children suffering from this condition [40]. It is wide-
ly known that obesity in the healthy child population is
connected with accelerated growth and puberty
processes. As of yet, no reports have been published on
growth and puberty in children with cystic fibrosis
combined with excess body mass, which may be con-
ducive to puberty normalization. The issue of growth
and puberty in children with cystic fibrosis thus
requires further detailed investigation under clinical
and auxological aspects.
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